When COVID-19 Confuses the Immune System: The Emerging Connection between Infection and Autoimmunity

A viral infection is supposed to follow a familiar script. A virus enters the body, the immune system recognizes the invader, and an elaborate defense begins. Antibodies attach to viral particles. Immune cells destroy infected cells. Inflammatory signals summon reinforcements. Eventually, the infection retreats, the alarm quiets and the immune system returns to surveillance.COVID-19 has shown how dramatically that script can change.

The Immune System Has a Difficult Job

The human immune system faces a remarkable identification problem. Every day, it must distinguish dangerous foreign material from the body's own cells. It must attack a virus without destroying the lung in which the virus is replicating. It must eliminate infected cells while preserving neighboring healthy tissue. And after the threat is gone, it must shut down much of the inflammatory machinery that made survival possible.

This discrimination is called immune tolerance. Tolerance is not passive. The body maintains multiple checkpoints that eliminate or restrain immune cells capable of attacking self-tissues. Regulatory cells suppress inappropriate immune activation. Molecular signals tell immune cells when to advance and when to stop.

But powerful infections can place this system under extraordinary pressure.SARS-CoV-2 enters cells through interactions involving ACE2, a protein found in tissues throughout the body. Although COVID-19 became known primarily as a respiratory illness, its biological effects can extend well beyond the lungs. The infection can involve vascular, cardiac, renal, gastrointestinal and neurological systems, either directly or through inflammatory and immune-mediated mechanisms.

As infected cells die, they release cellular contents that are normally hidden from immune surveillance. Inflammation recruits more immune cells. Antibody-producing B cells become highly active. Tissue damage reveals additional self-antigens. In most people, these processes resolve. But in a susceptible immune system, the boundary between attacking the virus and attacking the body may become less secure.

When a Virus Resembles Us

One possible explanation is a phenomenon called molecular mimicry. Viruses are built from proteins, and proteins are built from sequences of amino acids. The immune system recognizes small molecular fragments from these proteins. Occasionally, a fragment of a microbial protein resembles part of a human protein closely enough that an immune response against the microbe may also recognize human tissue.

It is biological mistaken identity.The idea predates COVID-19. The classic example is rheumatic fever, in which an immune response following infection with certain strains of Streptococcus can cross-react with tissues in the heart and other organs.

Researchers have identified similarities between portions of SARS-CoV-2 proteins and human proteins. Such overlap provides a plausible mechanism for cross-reactive immunity, although similarity alone does not prove that autoimmune disease will develop.

Most people infected with SARS-CoV-2 do not develop autoimmune illness. That fact is crucial. The immune system contains redundant layers of protection against self-attack. Molecular mimicry may become clinically important only when combined with other factors: genetic susceptibility, unusually intense inflammation, extensive tissue injury, impaired immune regulation or perhaps a history of previous immune challenges.

COVID-19 may therefore act less like a single switch and more like a stress test of immune tolerance.

The Fire That Outlasts the Spark

Early in the pandemic, physicians caring for critically ill patients encountered another feature of severe COVID-19: inflammation could become almost as dangerous as the infection itself. Immune cells communicate through chemical messengers called cytokines. Molecules such as interleukin-6 and tumor necrosis factor help coordinate the body's response to infection. At appropriate levels, these signals are essential. But when inflammatory networks become severely dysregulated, the same molecules can contribute to widespread tissue injury.

The phrase “cytokine storm” became popular during the pandemic, although immunologists have emphasized that severe COVID-19 is more complex than a simple excess of every inflammatory signal. Different patients may have different patterns of immune dysfunction.

Still, the central problem is clear: an immune response designed to protect the body can become poorly regulated and damage it. This intense inflammatory environment may also create favorable conditions for autoimmunity. Tissue destruction releases self-antigens. Large numbers of B cells are activated. Immune checkpoints may become less effective. The body can produce antibodies against its own proteins, phospholipids, nuclear material and even components of the immune system itself.

Yet an important distinction is often lost in public discussions: an autoantibody is not the same thing as an autoimmune disease. Autoantibodies can appear temporarily during infections. Some disappear as inflammation resolves. Others persist without causing recognizable disease. Only in certain circumstances do they appear to participate directly in tissue injury or signal a sustained breakdown of immune tolerance.

Understanding why some immune disturbances disappear while others become chronic is one of the most important unanswered questions left by the pandemic.

The Children Who Became Sick after They Had Recovered

One of the most striking clues that COVID-19 can disrupt immune regulation came not from the intensive care units treating acute pneumonia but from pediatric hospitals. Several weeks after waves of SARS-CoV-2 infection, physicians began seeing children with persistent fever, abdominal pain, rash, red eyes, low blood pressure and inflammation affecting multiple organs. Some developed shock or significant heart dysfunction.

Many no longer had active respiratory illness. The condition became known as multisystem inflammatory syndrome in children, or MIS-C.At first, doctors noticed similarities to Kawasaki disease, a rare inflammatory disorder that primarily affects young children and can injure the coronary arteries. But differences soon became apparent. Children with MIS-C were often older, had more gastrointestinal symptoms and were more likely to experience shock and clinically significant cardiac inflammation.

A related syndrome, MIS-A, was later recognized in adults. These syndromes provided a dramatic demonstration of delayed immune pathology. The infection could be mild, or even unnoticed, yet weeks later the immune system could generate a serious multisystem inflammatory illness. The virus had provided the spark. The immune response continued the fire.

A Growing List of Autoimmune Questions

During and after the pandemic, physicians reported numerous immune-mediated conditions following SARS-CoV-2 infection. Some patients developed antibodies associated with abnormal blood clotting. Cases of Guillain-Barré syndrome and other neurological inflammatory disorders were reported. Others developed inflammatory arthritis, immune destruction of blood cells, thyroid inflammation or features resembling systemic autoimmune diseases such as lupus.But the evidence must be interpreted carefully.

When a virus infects hundreds of millions of people, many illnesses will occur after infection simply by coincidence. A person may develop rheumatoid arthritis two months after COVID-19 without the infection having caused it. Timing alone cannot establish causation.

Researchers therefore look for several forms of evidence. Does the disease occur more frequently after infection than in comparable uninfected populations? Is there a plausible immune mechanism? Is the timing biologically consistent? Are particular antibodies, immune cells or inflammatory pathways involved?

For some postinfectious complications, the evidence is increasingly convincing. For others, the connection remains uncertain. Science rarely advances through a single dramatic discovery. More often, it advances by gradually separating meaningful signals from coincidence.

Autoimmune Disease Can Also Change the Course of COVID-19

The relationship between COVID-19 and autoimmunity does not travel in only one direction. People with autoimmune disease vary enormously in their risk from infection. The phrase “autoimmune patient” includes individuals with conditions ranging from relatively stable autoimmune thyroid disease to severe systemic lupus, inflammatory vascular disease or neurological autoimmunity requiring powerful immunosuppressive therapy.

Age, obesity, diabetes, cardiovascular disease and kidney disease remain important determinants of COVID-19 severity. But the activity of the autoimmune disease and the medications used to control it also matter. One particularly important example involves drugs that deplete B cells, such as rituximab. B cells are responsible for producing antibodies and contribute to immune memory. Depleting them can be highly effective against certain autoimmune diseases, but it can also reduce the body's ability to generate effective antibody responses to infection and vaccination.

Systemic corticosteroids present another apparent paradox. Chronic high-dose exposure can suppress antiviral defenses and increase susceptibility to infections. Yet corticosteroids became lifesaving treatments for selected patients hospitalized with severe COVID-19 who required respiratory support.

The contradiction disappears when timing is considered. Early in an infection, the body needs an effective antiviral defense. Later, in certain severely ill patients, excessive inflammation can become a major source of injury. A treatment that is harmful at one stage may be beneficial at another. Immunology is often a science of timing.

Vaccination and the Question of Rare Immune Reactions

COVID-19 vaccines introduced another difficult public conversation about immunity. When billions of vaccine doses are administered, rare adverse events become visible in ways that would be impossible in smaller populations. Researchers and safety surveillance systems have investigated reports of myocarditis, immune thrombocytopenia, Guillain-Barré syndrome, thyroid inflammation and other immune-mediated conditions after vaccination.

The challenge is separating events that are genuinely associated with vaccination from illnesses that happen to occur afterward. One association that has been characterized particularly carefully is myocarditis after mRNA vaccination. The risk has been concentrated primarily among adolescent and young adult males, especially following certain doses and schedules. Most recognized cases have improved clinically, although monitoring and long-term research remain important.

For most people, including many with autoimmune disease, the protection vaccination provides against severe COVID-19 outweighs the risk of rare immune complications. For patients taking certain immunosuppressive drugs, however, timing can matter because some therapies weaken vaccine responses.

The appropriate question is therefore rarely whether the immune system should be stimulated or suppressed in absolute terms. The more useful questions are: Which immune pathway? At what time? In which patient?

The Body's Defenses Do Not Exist in Isolation

The immune system does not operate separately from the rest of human physiology. Sleep deprivation alters immune signaling and can weaken vaccine responses. Smoking injures respiratory defenses and promotes chronic inflammation. Regular moderate physical activity improves metabolic health and influences immune regulation. Nutritional deficiencies can impair epithelial barriers and immune cell function.

Researchers are also studying the gut microbiome, the enormous community of bacteria, fungi and other microorganisms that lives within the gastrointestinal tract. These organisms interact continuously with the immune system. Both severe infections and autoimmune disorders have been associated with disruptions in microbial communities, raising questions about whether microbiome changes contribute to prolonged inflammation or failures of immune tolerance.

The answers are not yet clear. Vitamin supplements, probiotics and other immune-directed products are often marketed far ahead of the science. Correcting a genuine nutritional deficiency is important, but no supplement can guarantee protection from COVID-19 or prevent autoimmune disease. Similarly, microbiome science is promising but remains too young to support many of the sweeping claims made in consumer advertising.

Immune resilience is probably not produced by a single nutrient or microbial species. It emerges from a network that includes genetics, metabolism, sleep, nutrition, environmental exposures, microbial ecosystems and previous immune experiences.

The Pandemic's Larger Immunological Lesson

COVID-19 has become one of the largest natural experiments in the history of immunology. Billions of people encountered the same virus within a relatively short period of human history. Their responses varied enormously.

Some barely noticed the infection. Others developed pneumonia. Some experienced vascular or neurological complications. A small number developed delayed multisystem inflammatory syndromes. Others continued to experience symptoms long after the acute infection had passed.

Why?

Part of the answer lies in the virus. But much of it lies in the host. Each person's immune system carries a history: genes inherited from parents, infections encountered in childhood, vaccinations, environmental exposures, microbial communities, metabolic health and decades of immunological memory.SARS-CoV-2 entered that complicated landscape.

In most people, the immune system recognized the threat, controlled it and eventually restored equilibrium. In others, the response became excessive, misdirected or unusually persistent.

That may be the most important connection between COVID-19 and autoimmunity. The virus has shown, on an unprecedented scale, that recovering from an infection requires more than eliminating a pathogen. The immune system must also know when to stop fighting.

When that final step fails, the boundary between defense and disease can become dangerously thin.

Reference

1. Al-Beltagi M, Saeed NK, Bediwy AS. COVID-19 disease and autoimmune disorders: A mutual pathway. World J Methodol. 2022;12(4):200-223. Published 2022 Jul 20. doi:10.5662/wjm.v12.i4.200

2. Wang EY, Mao T, Klein J, et al. Diverse Functional Autoantibodies in Patients with COVID-19. Preprint. medRxiv. 2021;2020.12.10.20247205. Published 2021 Feb 1. doi:10.1101/2020.12.10.20247205

3. Bastard P, Rosen LB, Zhang Q, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4585. doi:10.1126/science.abd4585

4. Consiglio CR, Cotugno N, Sardh F, et al. The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19. Cell. 2020;183(4):968-981.e7. doi:10.1016/j.cell.2020.09.016

5. Bodansky A, Mettelman RC, Sabatino JJ Jr, et al. Molecular mimicry in multisystem inflammatory syndrome in children. Nature. 2024